Find a study
Browse recruiting studies near you — free to check, always your choice.
37 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
Testing how efimosfermin alfa compares with placebo for MASH with scarred liver tissue
📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
- Anxiety💵 May compensate
Transcranial Alternating Current Stimulation (tACS) for the Treatment of Anxiety in Veterans: An Open-Label Pilot Study
Testing a wearable brain stimulation device to treat anxiety in veterans
📍 Birmingham VA · Birmingham, AL · Get directions →
Transcranial alternating current stimulation (tACS) in a wearable brain stimulation device that delivers a low intensity, pulsed, alternating current via scalp electrodes. Prior sham-controlled clinical trials have shown the therapeutic effects and safety of tACS for the treatment of anxiety and depression.
- Anxiety💵 May compensate
Implementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
Testing different ways to deliver talk therapy skills for kids with anxiety
📍 Bradley Hospital · East Providence, RI · Get directions →
The purpose of this study is to test how the delivery of Cognitive Behavioral Therapy (CBT) for pediatric anxiety and OCD via different methods might increase its availability and effectiveness. CBT involves teaching the patient skills to enable them to gradually come into contact with feared situations.
- Anxiety💵 May compensate
Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders
Testing a non-invasive brain stimulation device to help treat mealtime anxiety in adults with eating
📍 Rogers Behavioral Health · Oconomowoc, WI · Get directions →
The study is to evaluate the feasibility of using a non-invasive brain stimulation device in a sample of inpatients with eating disorders (ED). The study will help researchers evaluate whether their device protocol is practical for eating disorder inpatients as a way to manage eating disorder and anxiety symptoms.
- Fatty liver disease (NASH/MASH)💵 May compensate
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Testing how insulin works in healthy people versus people at risk for type 2 diabetes
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.
- Fatty liver disease (NASH/MASH)💵 May compensate
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Testing how SGLT2 inhibitors work for fatty liver disease in obese teens
📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Fibrosis Lessens After Metabolic Surgery
Testing whether metabolic surgery can reduce liver scarring in obesity
📍 Banner Health Center · Phoenix, AZ · +3 more US sites · Get directions →
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity, diabetes, and dyslipidemia. MASLD is currently the most common cause of chronic liver disease affecting about 80% of people with obesity, ranging from simple fat deposits in the liver to Metabolic Dysfunction-Associated Steatohepatitis (MASH), cellular injury, advanced fibrosis, cirrhosis, or hepatocellular carcinoma.
- DepressionAnxiety💵 May compensate
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
Testing psilocybin-assisted therapy for depression and anxiety in people with advanced cancer
📍 MD Anderson Cancer Center · Houston, TX · Get directions →
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Testing whether pegozafermin is safe and works for MASH-related liver cirrhosis
📍 89bio Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH \[previously known as nonalcoholic steatohepatitis, NASH\]).
- DepressionAnxiety💵 May compensate
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
Testing psilocybin-assisted therapy for depression and anxiety in cancer survivors
📍 The University of Texas M. D. Anderson Cancer Center · Houston, TX · Get directions →
This clinical research study is to learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy for cancer survivors with depression and/or anxiety.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Testing efimosfermin in people with MASH-related compensated cirrhosis
📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
- COPD (chronic lung disease)💵 May compensate
PiMZ Longitudinal Cohort (PiMZ Logic)
Tracking how COPD affects people with the PiMZ form of alpha-1 anti-trypsin deficiency
📍 University of Alabama at Birmingham · Birmingham, AL · +4 more US sites · Get directions →
Alpha-1 Anti-trypsin Deficiency (AATD) is a genetic disease with lung and liver disease presentations. Presentations are variable in the heterozygous population, the most predominant genotype being PiMZ.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluating the Pharmacokinetics and Safety of Miricorilant
Testing how a drug works in the body and its safety in adults with MASH
📍 Site# 433 · San Antonio, TX · Get directions →
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Fatty liver disease (NASH/MASH)💵 May compensate
Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD
Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and
📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →
This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.
- COPD (chronic lung disease)💵 May compensate
Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass Exposure
Comparing inhaled triple versus double medicines for COPD lung airways after wood smoke exposure
📍 Insituto Nacional de Enfermedades Respiratorias "Ismael Cosío Villegas" · Mexico City, Tlalpan · Get directions →
This phase IV randomized controlled clinical trial intend to compare the effect of three close standard inhaled triple therapies and one close standard inhaled double therapy on the small airway in patients with Chronic Obstructive Pulmonary Disease (COPD-B) and chronic bronchitis without obstruction (BCNO) exposed to wood smoke. The treatment phase duration is of 3 months.
- DepressionAnxiety💵 May compensate
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
Testing whether pregnenolone pills affect brain function and depression in people with HIV
📍 Massachusetts General Hospital · Boston, MA · Get directions →
This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications.
- Fatty liver disease (NASH/MASH)💵 May compensate
Endoscopic Ultrasound Shear Wave Elastography Study
Testing an ultrasound imaging method during endoscopy to measure liver scarring
📍 Brigham and Women's Hospital · Boston, MA · +1 more US site · Get directions →
This study shall be a prospective, multicenter, single arm, consecutive, interventional study conducted in a post-market setting using commercially available devices. Consecutive, eligible patients with clinical suspicion of MASLD or MASH reporting for an endoscopic ultrasound and liver biopsy for evaluation of fibrosis will be enrolled.
- Fatty liver disease (NASH/MASH)💵 May compensate
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Testing how to predict liver outcomes in people with NASH and advanced scarring
📍 Mayo Clinic in Rochester · Rochester, MN · +1 more US site · Get directions →
Nonalcoholic Steatohepatitis (NASH) is a condition with increased amount of fat, inflammation and scarring in the liver. In compensated cirrhosis, the liver is coping with this damage and maintaining its important functions.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluation of Non-Invasive Tests for Metabolic Liver Disease
Testing blood and scan methods to diagnose and stage MASH
📍 Clinical Pharmacology of Miami · Miami, FL · +3 more US sites · Get directions →
The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.
- Migraine / chronic headache💵 May compensate
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Studying real-world results of migraine preventive medicines targeting CGRP
📍 University of Miami, Miller School of Medicine · Miami, FL · Get directions →
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
- Fatty liver disease (NASH/MASH)💵 May compensate
Milk Thistle Clinical Trial in Pediatric NAFLD
Testing milk thistle for children with fatty liver disease
📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →
Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Testing a medicine called efruxifermin in people with compensated liver scarring from NASH/MASH
📍 Akero Clinical Study Site · Birmingham, AL · +39 more US sites · Get directions →
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
- COPD (chronic lung disease)💵 May compensate
Routine vs On-demand ECMO for Lung Transplantation
Comparing routine versus on-demand ECMO during lung transplants for people with COPD
📍 Univeristy of Alberta & Alberta Health Services · Edmonton, Alberta · Get directions →
Lung transplantation is a complex procedure performed in patients with terminal lung disease. The transplant procedure stresses the patient's heart and lungs, which are already taxed by the underlying disease process.
- Fatty liver disease (NASH/MASH)💵 May compensate
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Testing whether survodutide helps adults with MASH and moderate to advanced liver scarring
📍 University of Alabama at Birmingham · Birmingham, AL · +39 more US sites · Get directions →
This study is open to adults who are at least 18 years old living with obesity and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function.
- Fatty liver disease (NASH/MASH)💵 May compensate
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Testing whether survodutide helps adults with NASH/MASH cirrhosis
📍 The Institute for Liver Health II DBA Arizona Clinical Trials · Peoria, AZ · +39 more US sites · Get directions →
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study.
- Fatty liver disease (NASH/MASH)💵 May compensate
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Testing the safety of an injected medicine in people with MASH and F2 or F3 scarring
📍 GSK Investigational Site · Arcadia, CA · +39 more US sites · Get directions →
This study will evaluate the safety and tolerability of Efimosfermin Alfa for participants with known or suspected MASH with fibrosis consistent with stage F2 or F3.
- COPD (chronic lung disease)💵 May compensate
Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
Testing a lung procedure to reduce lung trapping in severe COPD
📍 Beth Israel Deaconess Medical Center · Boston, MA · Get directions →
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided stapling along the lung fissures to reduce collateral ventilation with adhesions removal and determine whether this experimental strategy will improve outcomes after failed BLVR in patients with severe emphysema/COPD.
- Fatty liver disease (NASH/MASH)💵 May compensate
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Testing resmetirom in people with MASH-related liver scarring after liver transplant
📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Effect of Insulin Lowering on Lipogenesis
Testing whether lowering insulin for one week changes liver fat in people with obesity and MASLD
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.
- COPD (chronic lung disease)💵 May compensate
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
Studying whether sleep apnea together with COPD affects thinking in older veterans
📍 John D. Dingell VA Medical Center, Detroit, MI · Detroit, MI · Get directions →
Cognitive dysfunction in the aging Veteran population is a growing health concern in the Veterans Health System. It is not known whether OSA coexisting with COPD will enhance the risk for cognitive dysfunction.
- Fatty liver disease (NASH/MASH)💵 May compensate
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Testing whether a CT scan can sort people with suspected NASH by liver scarring and inflammation
📍 Arizona Liver Health · Chandler, AZ · +6 more US sites · Get directions →
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
- Type 2 diabetesFatty liver disease (NASH/MASH)💵 May compensate
Low-Dose Pioglitazone in Patients With NASH (AIM 2)
Testing a low-dose diabetes medicine to see effects on liver changes in NASH
📍 University of Florida · Gainesville, FL · Get directions →
To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).
- COPD (chronic lung disease)💵 May compensate
Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD
Testing nebulized long-acting breathing medicines vs usual short-acting ones in hospitalized COPD
📍 University of Tennessee Medical Center · Knoxville, TN · Get directions →
The purpose of this study is to assess the feasibility, safety and efficacy of a combination of nebulized Formoterol and Revefenacin among patients hospitalized for AECOPD compared with standard-of-care therapy with nebulized Albuterol and Ipratropium.
- Fatty liver disease (NASH/MASH)💵 May compensate
Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
Testing whether eating in an 8-hour window changes liver fat in people with fatty liver disease
📍 Weill Cornell Medicine · New York, NY · Get directions →
This study will assess the impact of time-restricted eating (8 hours of eating each day) with standard of care lifestyle recommendations (hypocaloric, Mediterranean diet and 30 minutes of exercise on at least 5 days/week) on the degree of fat in the liver as measured by magnetic resonance imaging.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Testing miricorilant’s effect on liver fat in people with MASH
📍 University of Missouri · Columbia, MO · Get directions →
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- COPD (chronic lung disease)💵 May compensate
Study of Clinical and Patient-reported Outcomes in Adults With Moderate to Severe COPD Treated With Breztri/Trixeo
Studying how adults with COPD feel and how their symptoms change over time
📍 Research Site · Buenos Aires, · Get directions →
Chronic Obstructive Pulmonary Disease is a leading cause of global morbidity and mortality, especially in low- and middle-income countries. Exacerbations accelerate disease progression and increase the risk of death.